Company Description
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States.
Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.
The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Allan Camaisa |
Contact Details
Address: 4475 Executive Drive, Suite 200 San Diego, California 92121 United States | |
| Phone | 858 794 9600 |
| Website | calidibio.com |
Stock Details
| Ticker Symbol | CLDI |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001855485 |
| ISIN Number | US3207031010 |
| Employer ID | 86-2967193 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Allan J. Camaisa | Chief Executive Officer and Chairman of the Board |
| Wendy Pizarro Campbell Esq. | Chief Administrative Officer, Chief Legal Officer, Chief Diversity Officer and Corporate Secretary |
| Dr. Boris Minev M.D., Ph.D. | President of Medical and Scientific Affairs and Interim Chief Medical Officer |
| Andrew C. Jackson | Chief Financial Officer |
| Dr. Amish Patel Ph.D. | Senior Vice President of Technical Operations |
| Stephen Thesing | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 22, 2024 | 8-K | Current Report |
| Aug 20, 2024 | 8-K | Current Report |
| Aug 20, 2024 | DEF 14A | Other definitive proxy statements |
| Aug 14, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 10-Q | Quarterly Report |
| Jul 29, 2024 | 8-K | Current Report |
| Jul 15, 2024 | 8-K | Current Report |
| Jul 8, 2024 | 8-K | Current Report |
| Jul 5, 2024 | 8-K | Current Report |
| Jun 26, 2024 | 8-K | Current Report |